3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
4
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Interventions
Temozolomide
29
Bevacizumab
14
Radiotherapy
12
Trastuzumab
10
Lomustine
9
Capecitabine
8
paclitaxel-Angiopep-2 conjugate
6
Nivolumab
6
pembrolizumab
5
dabrafenib
5
abemaciclib
5
Radiation
5
icotinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Lapatinib
4
Irinotecan
4
Flucytosine
4
Dianhydrogalactitol
4
Corticotropin-Releasing Hormone
4
Chlorotoxin
4
Carboplatin
4
vocimagene amiretrorepvec
3
verubulin
3
tucatinib
3
osimertinib
3
motexafin gadolinium
3
XL647
3
Spermine Synthase
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts